Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent.
about
Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discoveryThe microtubule depolymerizing agent CYT997 effectively kills acute myeloid leukemia cells via activation of caspases and inhibition of PI3K/Akt/mTOR pathway proteinsRecent advances in vascular disrupting agents in cancer therapy.Early investigational tubulin inhibitors as novel cancer therapeutics.Natural products against cancer angiogenesis.A cooperative polymeric platform for tumor-targeted drug delivery.
P2860
Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Phase I, pharmacokinetic and p ...... and vascular-disrupting agent.
@en
Phase I, pharmacokinetic and p ...... and vascular-disrupting agent.
@nl
type
label
Phase I, pharmacokinetic and p ...... and vascular-disrupting agent.
@en
Phase I, pharmacokinetic and p ...... and vascular-disrupting agent.
@nl
prefLabel
Phase I, pharmacokinetic and p ...... and vascular-disrupting agent.
@en
Phase I, pharmacokinetic and p ...... and vascular-disrupting agent.
@nl
P2093
P2860
P1476
Phase I, pharmacokinetic and p ...... and vascular-disrupting agent.
@en
P2093
Alessandra B Francesconi
Andrew Wilks
Dusan Kotasek
Gregg Smith
Jason D Lickliter
Matthew Burge
Paul A Vasey
P2860
P2888
P304
P356
10.1007/S10637-012-9813-Y
P577
2012-03-27T00:00:00Z